---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-023447"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:23:34.510549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quoin reports FY2024 net loss $9.0M; cash $14.1M; positive QRX003 whole-body data in Netherton

## Summary
- Cash of $14.1M at Dec 31, 2024 expected to fund operations into Q2 2026.
- Net loss FY2024 $9.0M vs $8.7M; Q4 loss $2.3M vs $2.0M year ago.
- First pediatric patient on whole-body QRX003 showed skin healing in 2 weeks, discontinued all prior meds, zero sleep disturbances.
- FDA cleared whole-body QRX003 study; to be led by Dr. Amy Paller at Northwestern University.
- Filed patent applications for topical rapamycin formulations targeting rare dermatological diseases.

## SEC filing metadata
- accession: 0001104659-25-023447
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/0001104659-25-023447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/tm259112d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-023447
- JSON: https://secwatch.observer/filing/0001104659-25-023447.json
- Plain text: https://secwatch.observer/filing/0001104659-25-023447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.